Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NVO 
Novo Nordisk A/S (NVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NVO (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $63.66
1 Year Target Price $63.66
| 4 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 29.2% | Avg. Invested days 77 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 247.11B USD | Price to earnings Ratio 14.42 | 1Y Target Price 63.66 |
Price to earnings Ratio 14.42 | 1Y Target Price 63.66 | ||
Volume (30-day avg) 12 | Beta 0.27 | 52 Weeks Range 44.55 - 134.90 | Updated Date 08/29/2025 |
52 Weeks Range 44.55 - 134.90 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 3.08% | Basic EPS (TTM) 3.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When Before Market | Estimate 6 | Actual 5.96 |
Profitability
Profit Margin 35.61% | Operating Margin (TTM) 43.52% |
Management Effectiveness
Return on Assets (TTM) 21.82% | Return on Equity (TTM) 79.17% |
Valuation
Trailing PE 14.42 | Forward PE 14.53 | Enterprise Value 259631577142 | Price to Sales(TTM) 0.79 |
Enterprise Value 259631577142 | Price to Sales(TTM) 0.79 | ||
Enterprise Value to Revenue 5.34 | Enterprise Value to EBITDA 10.79 | Shares Outstanding 3368560128 | Shares Floating 3187938882 |
Shares Outstanding 3368560128 | Shares Floating 3187938882 | ||
Percent Insiders 0.01 | Percent Institutions 9.34 |
Upturn AI SWOT
Novo Nordisk A/S
Company Overview
History and Background
Novo Nordisk A/S was founded in 1923. Originally known as Novo Terapeutisk Laboratorium, it merged with Nordisk Insulinlaboratorium in 1989 to form Novo Nordisk. The company initially focused on insulin production and has since expanded to cover a broader range of diabetes care and biopharmaceuticals.
Core Business Areas
- Diabetes Care: Novo Nordisk's primary focus is diabetes care, encompassing insulin, GLP-1 receptor agonists, oral antidiabetic agents, and diabetes devices.
- Obesity Care: Novo Nordisk is rapidly expanding in obesity care with products like Wegovy and Saxenda, targeting weight management.
- Biopharmaceuticals: This segment includes treatments for hemophilia, growth disorders, and other serious chronic diseases.
Leadership and Structure
The company is led by CEO Lars Fruergaard Ju00f8rgensen. The organizational structure is divided into global business areas responsible for commercial activities and global functions supporting these areas.
Top Products and Market Share
Key Offerings
- Ozempic: A GLP-1 receptor agonist for type 2 diabetes. Competitors include Eli Lilly's Trulicity and Amgen's Repatha. Ozempic controls the market with 50% in market share and has around 5 million users globally and generated approximately $8 billion in revenue in 2023.
- Rybelsus: The first oral GLP-1 receptor agonist for type 2 diabetes. Competitors include Merck's Januvia and SGLT2 inhibitors. The market share is around 10% and earned about $2 billion in revenue in 2023.
- Wegovy: A GLP-1 receptor agonist for chronic weight management. Competitors include Eli Lilly's Zepbound and other weight-loss medications. 15% market share with around 1.5 million users.
- NovoLog/NovoRapid: A fast-acting insulin analog for diabetes. Competitors include Eli Lilly's Humalog and Sanofi's Apidra. 5% market share.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in diabetes and obesity care, is experiencing significant growth driven by rising prevalence of these conditions globally. There is intense competition and regulatory scrutiny.
Positioning
Novo Nordisk is a leader in diabetes care and is rapidly gaining market share in obesity care. Its competitive advantage lies in its established brand, innovative products, and strong research and development capabilities.
Total Addressable Market (TAM)
The global diabetes and obesity market is estimated at over $100 billion. Novo Nordisk is positioned to capture a significant share of this market with its existing product portfolio and pipeline.
Upturn SWOT Analysis
Strengths
- Leading position in diabetes care
- Strong product portfolio and pipeline
- Established brand recognition
- Strong research and development capabilities
- Global presence and distribution network
Weaknesses
- Dependence on a few key products
- Exposure to pricing pressures and regulatory risks
- Potential competition from biosimilars
- Manufacturing capacity constraints for high-demand products
Opportunities
- Expanding into new therapeutic areas
- Growing obesity care market
- Developing innovative drug delivery systems
- Expanding into emerging markets
- Strategic partnerships and acquisitions
Threats
- Intense competition from other pharmaceutical companies
- Pricing pressures from healthcare payers
- Regulatory changes and patent expirations
- Economic downturns affecting healthcare spending
- Clinical trial failures
Competitors and Market Share
Key Competitors
- LLY
- SNY
- MRK
Competitive Landscape
Novo Nordisk benefits from its strong brand, innovative products, and global presence. However, it faces intense competition from other pharmaceutical companies, particularly Eli Lilly, Sanofi, and Merck.
Major Acquisitions
Dicerna Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions): 3300
- Strategic Rationale: To strengthen Novo Nordisk's RNAi capabilities and pipeline in chronic diseases, including diabetes and obesity.
Growth Trajectory and Initiatives
Historical Growth: Novo Nordisk has experienced consistent growth over the past decade, driven by its strong position in diabetes care and its expansion into obesity care.
Future Projections: Analysts project continued growth for Novo Nordisk, driven by strong demand for its diabetes and obesity care products and its innovative pipeline. Revenue growth is expected to be in the double digits over the next few years.
Recent Initiatives: Recent strategic initiatives include investments in research and development, acquisitions of complementary businesses, and expansion into emerging markets.
Summary
Novo Nordisk is a strong company with a leading position in the diabetes care market and growing presence in obesity care. Its innovative products and strong financial performance drive its success. The company must manage pricing pressures and competition, while capitalizing on growth opportunities in emerging markets and new therapeutic areas.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Novo Nordisk Annual Reports
- SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change, so consult a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Novo Nordisk A/S
Exchange NYSE | Headquaters - | ||
IPO Launch date 1982-01-04 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 78387 | Website https://www.novonordisk.com |
Full time employees 78387 | Website https://www.novonordisk.com | ||
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.